EMEA Recommends Marketing Authorisation Of Ipsen’s Adenuric(R) (Febuxostat) For The Treatment Of Chronic Hyperuricaemia In Gout, Europe
Feb 26th 2008Drug InformationGout
Ipsen (Paris:IPN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) provided a positive opinion for Adenuric® (febuxostat) 80 mg and 120 mg tablets for the treatment of chronic hyperuricaemia in gout and recommended it for marketing authorisation. The CHMP recommendation will now be forwarded to the European Commission for final marketing approval, which typically occurs within 60 to 90 days.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
